Back to News
Market Impact: 0.42
Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer
Source: benzinga.com
Healthcare & BiotechProduct Launches
The FDA granted full approval for Eli Lilly's Inluriyo (imlunestrant), in combination with Verzenio (abemaciclib), for previously treated breast cancer patients. The approval expands Lilly's oncology portfolio and creates a new commercial opportunity in a significant breast-cancer treatment segment.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
LLY0.82
More News
- Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs
- Our top 10 things to watch in the stock market Friday
- Why is Hims & Hers Health stock rallying today?
- Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the Evidence
- Here's a rapid-fire update on all 31 of our stocks, including 2 to buy now
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction